Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk by Luca Miele, Cristina Bosetti, Federica Turati, Gianlodovico Rapaccini, Antonio Gasbarrini, Carlo La Vecchia, Stefania Boccia, Antonio Grieco

“…Metabolic conditions, including type 2 diabetes, have been related to hepatocellular carcinoma (HCC) risk. We have further analyzed the role of diabetes and antidiabetic treatments on HCC. …”
Get full text

Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer by Qinyuan Gong, Qinyuan Gong, Rongzhen Xu, Rongzhen Xu

“…In contrast, K102-Env markedly increased in patients with PDAC, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC) compared with healthy controls. …”
Get full text

Metformin and the risk of malignant tumors of digestive system: a mendelian randomization study by Ping Liu, Junqi Xiao, Jinghuang Xiao, Jumei Zhou

“…No causal relationship was found for hepatocellular carcinoma, gastric cancer, pancreatic cancer, or other digestive system cancers. …”
Get full text

Targeting Toll-like receptor 4 and microbiota dysregulation: a new frontier in nonalcoholic fatty liver disease management by K.B. Kvit

“…It encompasses a spectrum of disorders, ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma, often associated with metabolic syndrome and insulin resistance. …”
Get full text

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease by Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S, Chen Z, Wang Q, Xu J, Tu Q, Chen H, Zhu L

“…Yun Mao,1,* Huilan Chen,1,* Weihan Zhu,2 Shunlan Ni,3 Shengnan Luo,3 Shiyue Tang,3 Zhiyi Chen,4 Qin Wang,3 Jinxian Xu,3 Qi Tu,5 Haijun Chen,3,* Lujian Zhu3,* 1Department of Gerontology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China; 2The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 3Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China; 4Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China; 5Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lujian Zhu; Haijun Chen, Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China, Email zhulj_brave@163.com; 19564367335@163.comAbstract: Chronic liver disease ranks as the 11th leading cause of death worldwide, while hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality, representing a substantial risk to public health. …”
Get full text

Prevalence of Hepatitis C Virus Infection in Cancer Patients: A Cross-sectional Study from Regional Cancer Care Centre, Gujarat, India by Hirenkumar Ashokbhai Patel, Foram Maulin Patel

“…It is one of the major risk factors for acute to chronic liver diseases, such as altered liver functions, chronic hepatitis, cirrhosis, hepatocellular carcinoma and liver failure. Additionally, the HCV poses significant risks to cancer patients undergoing treatment. …”
Get full text

The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells by Sabrina Bimonte, Maddalena Leongito, Antonio Barbieri, Vitale del Vecchio, Michela Falco, Aldo Giudice, Raffaele Palaia, Vittorio Albino, Raimondo Di Giacomo, Antonella Petrillo, Vincenza Granata, Francesco Izzo

“…Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide malignancy and the third leading cause of cancer death in patients. …”
Get full text

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion by V. V. Tsukanov, M. F. Osipenko, E. V. Beloborodova, M. A. Livzan, I. B. Khlynov, S. A. Alekseenko, Yu. P. Sivolap, J. L. Tonkikh, A. V. Vasyutin

“…In the treatment of NAFLD, diet and lifestyle modification, weight loss, the use of insulin sensitizers, vitamin E, statins (in the presence of hyperlipidemia) and drugs with metabolic activity are effective.Currently, a point of view is being actively expressed about the synergism of the action of alcohol and the metabolic syndrome on the development of fibrosis, cirrhosis, and hepatocellular carcinoma. The current international consensus recommends a change in the nomenclature of NAFLD and ALD and proposes the terms “metabolically associated steatotic liver disease” and “metabolically associated alcoholic liver disease”.Conclusion. …”
Get full text

Nursing management for enhanced recovery after liver transplantation in a patient with cavernous transformation of the portal vein (1例成人门静脉海绵样变性患者行肝移植的加速康复护理)... by WANG Ting (王婷), LUO Hongping (罗鸿萍)

“…This paper reviewed the clinical data of a hepatocellular carcinoma (BCLC stage A) patient with hepatitis C virus-related cirrhosis, cavernous transformation of the portal vein and portal hypertension, and summarized the nursing management for enhanced recovery after liver transplantation. …”
Get full text

Pathological Diagnosis of Hepatocellular Cellular Adenoma according to the Clinical Context by Paulette Bioulac-Sage, Christine Sempoux, Laurent Possenti, Nora Frulio, Hervé Laumonier, Christophe Laurent, Laurence Chiche, Jean Frédéric Blanc, Jean Saric, Hervé Trillaud, Brigitte Le Bail, Charles Balabaud

“…When the whole nodule is a hepatocellular carcinoma, it is extremely difficult to prove that it is the consequence of a former HCA. …”
Get full text

HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007) by Raj Kalkeri, Junzhong Peng, Chunsheng Huang, Zhaohui Cai, Roger G. Ptak, Mark J. Suto

“…Approximately 257 million people chronically infected with hepatitis B virus (HBV) worldwide are at risk of developing hepatocellular carcinoma (HCC). However, despite the availability of potent nucleoside/tide inhibitors, currently there are no curative therapies for chronic HBV infections. …”
Get full text

Increased Anti-Proliferation Performance of NanoChitosan-Moringa Seeds Extract and Co-Treatment with Doxorubicin in Liver Cancer Cells by Hendra Susanto, Moch Sholeh, Agustina Tri Endharti, Nik Ahmad Nizam Nik Malek, Sa’diyatul Rizqie Amaliyah Firdaus, Adeodatus Yuda Handaya, Ahmad Taufiq

“… Hepatocellular carcinoma (HCC) with high epidemiological report data. …”
Get full text

CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors by Olga R. Brook, Eavan Thornton, Mishal Mendiratta-Lala, Anand Mahadevan, Vassilious Raptopoulos, Alexander Brook, Robert Najarian, Robert Sheiman, Bettina Siewert

“…Results. 36 subjects with hepatocellular carcinoma (HCC), 25 with liver metastases, and seven with cholangiocarcinoma (CCC) were included in study. …”
Get full text

Comprehensive analysis of inhibin-β A as a potential biomarker for gastrointestinal tract cancers through bioinformatics approaches by Rohit Kumar Verma, Prashant Kumar Srivastava, Ashutosh Singh

“…The results revealed consistent upregulation of INHBA in all TCGA GI tract cancers, except for liver hepatocellular carcinoma, where it showed downregulation compared to normal tissues, along with GTEx normal samples. …”
Get full text

Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts by Kelley Weinfurtner, David Tischfield, George McClung, Jennifer Crainic, John Gordan, Jing Jiao, Emma E. Furth, Wuyan Li, Erena Tuzneen Supan, Gregory J. Nadolski, Stephen J. Hunt, David E. Kaplan, Terence P.F. Gade

“…Background & Aims: Response to immunotherapy in hepatocellular carcinoma (HCC) is suboptimal with no biomarkers to guide patient selection. …”
Get full text

Novel (±)-trans-β-lactam ureas: Synthesis, in silico and in vitro biological profiling by Jurin Mladenka, Stepanić Višnja, Bojanić Krunoslav, Vadlja Denis, Kontrec Darko, Dražić Tonko, Roje Marin

“…Several of the newly synthesized trans-b-lactam ureas 4a–c, 4f, 4h, 4n, 4o, 4p, and 4s were evaluated for in vitro antiproliferative activity against liver hepatocellular carcinoma (HepG2), ovarian carcinoma (A2780), breast adenocarcinoma (MCF7) and untransformed human fibroblasts (HFF1). …”
Get full text

PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity by Heng Zhang, Hui Zheng, Lin Guo, Ying Tong, Xiaolu Ma, Yanchun Wang, Renquan Lu, Cuncun Chen, Suhong Xie

“…However, the impact of anti-PD-1 therapy on host humoral immunity in humans during cancer immunotherapy requires further investigation.Methods We evaluated immunoglobulin titers by ELISA and screened the immune landscape of immune cells from 25 healthy donors and 50 cases including 25 new-onset hepatocellular carcinoma (HCC) patients prior to systemic treatment and 25 HCC patients undergoing anti-PD-1 therapy by multicolor flow cytometry. …”
Get full text

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion by Chongwei Xie, Bing Zhou, Da Yao, Xin Wang, Lihong Zhong, Chuanghua Qiu, Junfang Zhang

“…Hepatitis B virus (HBV) represents one of the major pathogenic factor that leads to chronic liver diseases and the development of hepatocellular carcinoma (HCC). The currently approved anti-HBV drugs cannot eradicate the virus or block the development of HCC. …”
Get full text

Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis... by Sheng-Hung Chen, Hsueh-Chou Lai, Wen-Pang Su, Jung-Ta Kao, Po-Heng Chuang, Wei-Fan Hsu, Hung-Wei Wang, Tsung-Lin Hsieh, Hung-Yao Chen, Cheng-Yuan Peng

“…Cox regression and random forest models identified the key factors, including longitudinal LS and noninvasive test results, that could predict LREs, including hepatocellular carcinoma, during prespecified follow-ups from 2010 to 2021. …”
Get full text

ERG mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFRα+ cancer-associated fibroblasts during hepatocarcinogenesis by Haoran Bai, Xinyu Zhu, Lu Gao, Shiyao Feng, Hegen Li, Xiaoqiang Gu, Jiahua Xu, Chen Zong, Xiaojuan Hou, Xue Yang, Jinghua Jiang, Qiudong Zhao, Lixin Wei, Li Zhang, Zhipeng Han, Wenting Liu, Jianxin Qian

“…Abstract Cancer-associated fibroblasts (CAFs) play important roles in the occurrence and development of hepatocellular carcinoma (HCC) and are a key component of the immunosuppressive microenvironment. …”
Get full text